YARAL Pharma

Executive Summary

YARAL Pharma Inc., the U.S. generics subsidiary of Swiss multinational IBSA, is dedicated to expanding patient access to affordable, high-quality authorized generics (AGs) and complex generic medicines. Founded in 2019 and headquartered in San Diego, the company focuses on therapeutic areas including pain, endocrinology, and inflammatory diseases. By leveraging IBSA's expertise and pipeline, YARAL aims to deliver cost-effective alternatives to branded drugs while maintaining high quality and regulatory compliance. Its patient-centered approach and emphasis on innovation position it as a competitive player in the U.S. generics market, particularly in complex generics which typically face higher barriers to entry.

Upcoming Catalysts (preview)

• Q3 2026Launch of Complex Generic Product in Endocrinology60% success
• Q1 2027FDA Approval for an Authorized Generic in Inflammatory Diseases55% success
• TBDStrategic Partnership or Licensing Deal for Pipeline Expansion50% success